Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis
Anne Knisely(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Steven Y. Huang(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Jolyn Taylor, Sara Hull(The University of Texas MD Anderson Cancer Center), Emily Hinchcliff(The University of Texas MD Anderson Cancer Center), Rahul A. Sheth(Massachusetts General Hospital), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Kathleen M. Schmeler(The University of Texas MD Anderson Cancer Center), Bryan Fellman(The University of Texas MD Anderson Cancer Center), Kathryn Lito(The University of Texas MD Anderson Cancer Center), Ann Mosley(The University of Texas MD Anderson Cancer Center), Anil K. Sood(The University of Texas MD Anderson Cancer Center)
Cited by 10
Related Papers
Monitoring dopants by Raman scattering in an electrochemically top-gated graphene transistor
|Nature Nanotechnology|2008|3.6k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Paraneoplastic Thrombocytosis in Ovarian Cancer
|New England Journal of Medicine|2012|822